NT-proBNP measured early after high-risk MI associated with further CV outcomes

Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial

Literature - Jering KS, Claggett BL, Pfeffer MA, et al. - Circ Heart Fail. 2023 May;16(5):e010259. doi: 10.1161/CIRCHEARTFAILURE.122.010259.


Patients who have experienced an acute myocardial infarction (MI) have an increased risk of further MI, stroke, HF and death, especially sudden death [1-5]. However, only a subset of patients, even after high-risk MI, experience these events, indicating a need for risk stratification in post-MI surveillance and treatment [4-9]. NT-proBNP is used as a prognostic marker of death and HF across multiple populations [10-11]. It remains unclear what the relationship is between NT-proBNP and recurrent MI and stroke in patients with ACS.

Aim of the study

The investigators examined the relationship between NT-proBNP and CV outcomes in patients following high-risk acute MI from the PARADISE-MI trial.



PARADISE-MI (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction) was a multicenter, double-blind, active comparator, randomized trial that compared the efficacy and safety of sacubitril/valsartan (97 mg sacubitril/93 mg valsartan twice daily) with ramipril (5 mg twice daily) in adult patients with a spontaneous acute MI complicated with LVEF ≤40% and/or pulmonary congestion, and ≥1 of 8 risk-augmenting factors. Patients with prior history of HF were excluded. In this prespecified subanalysis, a total of 1129 patients were included. Blood samples for NT-proBNP and hs-cTnT measurements were obtained within the first week of an MI. Data were analyzed with NT-proBNP as continuous variable or according to NT-proBNP quartiles (quartile 1: ≤896 ng/L; quartile 2: ≤897-1757 ng/L; quartile 3: 1758-3462 ng/L; quartile 4: >3462 ng/L). The median follow-up period was 29 months.


The primary outcome was a composite of CV mortality or incident HF (hospitalization or outpatient episode of symptomatic HF), analyzed as time-to-first event. Key secondary outcomes were CV mortality; HF hospitalization; all-cause mortality; and the composite of CV mortality, nonfatal MI or stroke.

Main results

NT-proBNP and clinical outcomes

  • During follow-up, the primary composite outcome occurred in 147 patients (13.0%).
  • The adjusted incidence rate of the primary composite outcome increased across NT-proBNP quartiles (2.0 per 100py; 3.7 per 100py; 6.8 per 100py; and 10.8 per 100py; for quartile 1, 2, 3, and 4, respectively).
  • There was an association of log-transformed NT-proBNP with the primary composite outcome (adjusted HR: 1.44 per doubling of NT-proBNP; 95%CI: 1.22-1.69), which was independent of log-transformed hs-cTnT and other clinical characteristics. Similar results were obtained for key secondary outcomes.
  • NT-proBNP did not modify the effects of sacubitril/valsartan vs. ramipril on the primary composite outcome (P for interaction=0.46).
  • A total of 79 patients (7.0%) died. The incidence rate of all-cause mortality increased across NT-proBNP quartiles. This was mainly driven by the higher proportion of patients with CV-mortality across higher NT-proBNP quartiles.

Modeling risk for all-cause mortality

  • Model discrimination for all-cause mortality with only log-transformed NT-proBNP did not differ from other risk stratification models such as GRACE 2.0 score (P=0.43) and TRA 2°P-TIMI score (P=0.67).
  • The addition of log-transformed NT-proBNP to TRA 2°P-TIMI score improved model predication for all-cause mortality (C statistic: 0.74; 95%CI: 0.69-0.80 vs. C statistic: 0.67; 95%CI: 0.61-0.73; with and without NT-proBNP, respectively; P=0.007).
  • The addition of log-transformed NT-proBNP did not improve the discrimination performance of GRACE 2.0 score (C statistic: 0.71; 95%CI: 0.65-0.77 vs. C statistic: 0.66; 95%CI: 0.59-0.73; with and without NT-proBNP, respectively; P=0.12).


In a prespecified analysis using data of the PARADISE-MI trial, NT-proBNP measured within the first week of a high-risk MI was associated with the primary composite outcome of CV mortality or incident HF, independent of hs-cTnT. Moreover, model discrimination for all-cause mortality with only early NT-proBNP measurements performed similar to well-validated risk scores such as GRACE 2.0 or TRA 2°P-TIMI in this high-risk post-MI patient population. The authors state that “our findings seem to support the recommendation for NT-proBNP measurement following MI to assist in risk stratification”.


1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2022 update: a report from the American Heart Association. Circulation. 2022;145:e153–e639.

2. Peters SAE, Colantonio LD, Dai Y, et al. Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. Circulation. 2021;143:650–660.

3. Adabag AS, Therneau TM, Gersh BJ, et al. Sudden death after myocardial infarction. JAMA. 2008;300:2022–2029.

4. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36:1163–1170.

5. Zaman S, Kovoor P. Sudden cardiac death early after myocardial infarction: pathogenesis, risk stratification, and primary prevention. Circulation. 2014;129:2426–2435.

6. Lewis EF, Velazquez EJ, Solomon SD, et al. Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. Eur Heart J. 2008;29:748–756

7. Steg PG, Dabbous OH, Feldman LJ, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109:494–499.

8. Shah RV, Holmes D, Anderson M, et al. Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. Circ Heart Fail. 2012;5:693–702.

9. Dunlay SM, Weston SA, Killian JM, et al. Thirty-day rehospitalizations after acute myocardial infarction: a cohort study. Ann Intern Med. 2012;157:11–18.

10. Fulks M, Kaufman V, Clark M, Stout RL. NT-proBNP predicts all-cause mortality in a population of insurance applicants, follow-up analysis and further observations. J Insur Med. 2017;47:107–113.

11. Chow SL, Maisel AS, Anand I, et al. Role of biomarkers for the prevention, assessment, and management of heart failure: a scientific statement from the American Heart Association. Circulation. 2017;135:e1054–e1091.

Find this article online at Circ Heart Fail.

Facebook Comments


We’re glad to see you’re enjoying PACE-CME…
but how about a more personalized experience?

Register for free